Evoke Pharma (NASDAQ:EVOK) Shares Set to Reverse Split on Thursday, August 1st

Shares of Evoke Pharma, Inc. (NASDAQ:EVOK) are going to reverse split on Thursday, August 1st. The 1-12 reverse split was announced on Thursday, August 1st. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, August 1st.

Evoke Pharma Stock Performance

EVOK stock traded down $0.08 during midday trading on Tuesday, reaching $0.42. 112,058 shares of the company’s stock traded hands, compared to its average volume of 42,557. The company has a 50-day moving average price of $0.52 and a two-hundred day moving average price of $0.57. Evoke Pharma has a 52 week low of $0.36 and a 52 week high of $1.67. The firm has a market capitalization of $3.59 million, a PE ratio of -0.23 and a beta of 0.38.

Evoke Pharma (NASDAQ:EVOK) last issued its earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter. Evoke Pharma had a negative net margin of 116.75% and a negative return on equity of 4,908.09%. The business had revenue of $1.74 million for the quarter.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on shares of Evoke Pharma in a report on Tuesday, July 23rd. They set a “sell” rating on the stock.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.